Gilead Sciences (GILD) Shares are Up 0.96%

Gilead Sciences (GILD) has been under a strong bear grip, hence the stock is down -0.71% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.43% in the past 1 week. The stock has risen by 0.96% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.72% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.32% and the 50-Day Moving Average is 2.5%.The 200 Day SMA reached 10.18% Gilead Sciences Inc. has dropped 4.08% during the last 3-month period . Year-to-Date the stock performance stands at -20.83%.


Gilead Sciences (GILD) : The highest level Gilead Sciences (GILD) is projected to reach is $122 for the short term and the lowest estimate is at $91. The consolidated price target from 13 rating analysts who initiate coverage on the stock is $109 and the possibility the share price can swing is $8.81.

For the current week, the company shares have a recommendation consensus of Buy. Gilead Sciences (NASDAQ:GILD): stock was range-bound between the intraday low of $78.41 and the intraday high of $79.19 after having opened at $78.85 on Fridays session. The stock finally closed in the red at $78.85, a loss of -0.05%. The stock remained in the red for the whole trading day. The total traded volume was 10,307,872 shares. The stock failed to cross $79.19 in Fridays trading. The stocks closing price on Thursday was $78.84.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.